Nurix Therapeutics (NRIX) to Release Quarterly Earnings on Thursday

Nurix Therapeutics (NASDAQ:NRIX) is expected to announce its earnings results on Thursday, February 20th. Analysts expect the company to announce earnings of ($0.67) per share for the quarter.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. On average, analysts expect Nurix Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Nurix Therapeutics Stock Up 0.1 %

Shares of NASDAQ:NRIX opened at $17.59 on Tuesday. Nurix Therapeutics has a 52-week low of $9.22 and a 52-week high of $29.56. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -6.09 and a beta of 2.14. The business has a 50-day moving average price of $19.37 and a 200-day moving average price of $22.11.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 2,811 shares of the company’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the transaction, the chief financial officer now owns 39,549 shares of the company’s stock, valued at $785,047.65. This represents a 6.64 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares in the company, valued at approximately $1,110,349.45. This trade represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. 7.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on NRIX. Royal Bank of Canada raised their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Stephens reissued an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a report on Tuesday, January 21st. JPMorgan Chase & Co. cut their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. HC Wainwright boosted their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, BTIG Research assumed coverage on Nurix Therapeutics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, Nurix Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $31.81.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.